Immuron Limited (ASX: IMC) is heading to market with a capital raising, with the Australian Stock Exchange granting the company a trading halt this morning.
Immuron's shares are currently in pre-open.
Towards the end of 2013 the company obtained approval to sell its Travelan diarrhoea preventative in Canada, through partner Paladin Labs Inc.
The authorization granted is for tablets comprising 200 milligrams of Immuron’s hyperimmune bovine colostrum.
In Canada, Travelan is classified as a natural health product and will be available to patients over the counter without prescription.
The halt will remain in place until the opening of trade on Wednesday 22nd January 2014, or earlier if an announcement is made to the market.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.